Improving the evaluation of new cancer treatments: challenges and opportunities

Mace L Rothenberg; David P Carbone; David H Johnson

doi:10.1038/nrc1047

Improving the evaluation of new cancer treatments: challenges and opportunities

Nat Rev Cancer. 2003 Apr;3(4):303-9. doi: 10.1038/nrc1047.

Authors

Mace L Rothenberg¹, David P Carbone, David H Johnson

Affiliation

¹ Vanderbilt-Ingram Cancer Center, 777 Preston Research Building, Nashville, Tennessee 37232-6307, USA. [email protected]

PMID: 12671669
DOI: 10.1038/nrc1047

Abstract

There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic / standards*
Drug Evaluation, Preclinical / methods
Gene Expression Profiling / methods
Humans
Neoplasms / drug therapy*
Neoplasms / genetics
Research Design / standards*

Substances

Antineoplastic Agents